Menü
sharewise zieht um Am Wochenende vom 22./23. August wird das neue sharewise die Hauptseite. Schau es dir jetzt an und sag uns, was dir fehlt. Zum neuen sharewise Was sich ändert
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

AT&T Stock: Bull vs. Bear


Long-term shareholders in AT (NYSE: T) don't have much to be happy about. Against the backdrop of the S 500 index's 166% rally over the last decade, the telecom company's share price has fallen by roughly 44%. The stock is also down 20.5% this year alone.

Is AT a smart buy now considering its big dividend yield and meager price-to-earnings ratio, or is it a value trap destined to serve up even more disappointment for shareholders? Two Motley Fool contributors have vastly different takes on where this telecom stock is headed. 

Keith NoonanNo doubt about it, AT has its share of problems. The company still has a huge amount of debt on its books, its history of acquisitions is littered with duds, and its sales and earnings growth will likely proceed AT slow paces even in optimistic scenarios due to the competitive environments of the categories it operates in. 

Continue reading


Source Fool.com

Allergy Therapeutics PLC Aktie

0,053 €
0,00 %
Der Allergy Therapeutics PLC Kurs bewegt sich nicht, bleibt unverändert seit dem Vortag.

Like: 0
T
Teilen

Kommentare